263 results on '"Lewis, Ned"'
Search Results
2. Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use
3. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021
4. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021
5. Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023.
6. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting
7. Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age
8. Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023
9. Birth outcomes following immunization of pregnant women with pandemic H1N1 influenza vaccine 2009–2010
10. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak--United States, May 22-October 21, 2022
11. Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With Coronavirus Disease 2019—VISION Network, 10 States, June 2021–March 2023
12. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
13. No association between influenza vaccination during pregnancy and adverse birth outcomes
14. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines
15. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance--VISION Network, 10 States, December 2021-August 2022
16. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated--VISION Network, 10 States, December 2021-June 2022
17. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents
18. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
19. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
20. Kaiser Permanente Northern California pregnancy database: Description and proof of concept study
21. Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers
22. Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19–Associated Encounters in Adults During Delta and Omicron Predominance
23. Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network
24. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
25. Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States
26. 2322. Effectiveness of Recombinant Influenza Vaccine vs. Standard Dose Inactivated Influenza Vaccines Against Hospitalized Influenza-Related Outcomes in Adults: A Cluster Randomized Trial
27. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance--VISION Network, 10 States, August 2021-January 2022
28. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19--Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance--VISION Network, 10 States, August 2021-January 2022
29. Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19—VISION Network, August 2021 to March 2022
30. Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use
31. Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021
32. Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods
33. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
34. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States
35. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults--Nine States, January-September 2021
36. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity--Nine States, January-September 2021
37. Safety of COVID-19 mRNA Vaccination Among Young Children in the Vaccine Safety Datalink.
38. COVID-19 Vaccination Coverage Among Insured Persons Aged [greater than or equal to] 16 Years, by Race/Ethnicity and Other Selected Characteristics--Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021
39. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
40. Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years
41. Recurrent Guillain-Barré Syndrome Following Vaccination
42. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
43. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022
44. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine
45. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
46. Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study
47. Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems
48. Guillain-Barré Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink
49. 22. An Innovative Approach to Examining the Waning of Vaccine Effectiveness Using Automated Healthcare Data
50. Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.